MERCK CO. DL-,01/ US58933Y1055 /
25/05/2024 12:50:40 | Chg. -0.200 | Volume | Bid12:50:40 | Ask12:50:40 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
118.800EUR | -0.17% | - Turnover: - |
118.800Bid Size: - | 119.800Ask Size: - | 302.49 bill.EUR | - | - |
GlobeNewswire
07/05
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
06/05
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
06/03
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Can...
GlobeNewswire
04/03
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
21/12/2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
19/12/2023
Unnatural Products, Inc. Announces $32 Million in Series A Funding Led by Merck Global Health Innova...
GlobeNewswire
14/12/2023
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
12/12/2023
C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degr...
GlobeNewswire
05/12/2023
HiberCell, Inc. Announces Clinical Collaboration with Merck to Evaluate HC-7366, an Activator of ISR...
GlobeNewswire
04/12/2023
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
GlobeNewswire
13/11/2023
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire
17/10/2023
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA